Vynca wrote down
your wishes

The origin story is unusually specific, which is a good sign, because vague origin stories usually mean the company reverse-engineered its mission from a pitch deck. In 2013, three fellows in Stanford's Biodesign program - a fellowship famous for producing medical companies the way certain zip codes produce venture capitalists - were talking to Dr. Allen Namath, a critical care physician. He told them about a patient who had been resuscitated against their documented wishes. The advance directive existed. It just wasn't in the electronic health record at the moment a team of people had to decide, in seconds, whether to restart a heart.

That is the whole problem, and it is worth sitting with, because it is not a medical problem. Nobody lacked the skill to honor the patient's wishes. They lacked the wishes. Or rather, the wishes were sitting in a filing cabinet, or a lawyer's office, or a drawer at home, which for operational purposes is the same as not existing. This is a data-portability problem wearing the costume of a life-and-death drama, and Vynca's founders - Ryan Van Wert, Rush Bartlett, and Namath - correctly diagnosed it as such.

So Vynca started as software. The product captured a patient's advance care plan - their directives, their goals, the specific texture of what "enough" means to them - and made it accessible inside the EHR, so that the clinician standing over you at 2 a.m. could actually see it. This is deeply unglamorous work. It involves interoperability, which is the medical-software equivalent of plumbing: nobody thanks you for it, everybody notices when it fails, and it is much harder than it looks. Vynca did it, at scale, and the number it likes to cite - more than one million unique advance care plans delivered across all 50 states - is the kind of statistic that sounds like marketing until you remember each one represents a person who wrote down what they wanted and a system that can now find it.

Now, if the story ended there, Vynca would be a perfectly respectable health-IT vendor. Sell software to hospitals, book recurring revenue, grow at a defensible rate, get acquired by a larger health-IT vendor in the fullness of time. It is a fine business model. It is also not what happened.

In 2021, Vynca acquired ReSolutionCare, a Northern California palliative care practice founded in 2014 by Dr. Michael Fratkin. This is the moment the company stopped being a software company. Buying a clinical practice means you now employ the nurses, the physicians, the social workers, the chaplains. You are on the hook for actual patients in actual homes, which is a categorically harder business than selling a subscription. Code scales beautifully. Care does not - care scales the way trust scales, which is to say slowly, one home visit at a time.

Why do it, then? Because you cannot fix serious illness care from the sidelines. Palliative care - and this is the word Vynca has organized itself around - is one of the most misunderstood terms in medicine. People hear it and think hospice, think giving up, think the part of the story where the music turns sad. It actually means something more useful: treat the whole person, manage the symptoms, honor the goals, address the physical and emotional and spiritual and social all at once. It is care for people with serious illness who are, importantly, still very much living.

By 2022, Vynca was delivering this care - in homes and over video - across California, Oregon, Washington, Utah, and Idaho. It renamed itself VyncaCare, which was less a rebrand than a confession: we are not just software anymore, we are care, and the name should say so. It raised $30 million that January, led by Questa Capital, to build out the platform. And in 2023, Dr. Darren Schulte took over as CEO from co-founder Van Wert, with a mandate he describes as redesigning serious illness care around patients' changing needs.

That phrase - changing needs - is the entire thesis compressed into two words. Serious illness is not a fixed state. What a patient wants in month one is not what they want in month six, and a care model that can't flex with them isn't really honoring anyone's wishes; it's just honoring the version of them that happened to fill out a form. Flexibility, here, is not a nice-to-have. It is the product.

Vynca sells to health plans, health systems, and risk-bearing entities - the organizations that are financially responsible for populations of patients, including the sickest and most expensive ones. Patients with congestive heart failure, cancer, end-stage renal disease. This is the B2B2C model: Vynca contracts with a payer like Regence, which in 2025 opened Vynca's telehealth palliative care to its members, and the payer's members get the care.

The economics contain what looks like a paradox and isn't. The United States spends staggering sums in the last months of life, frequently on interventions patients never asked for and wouldn't have chosen. Aggressive care that no one wanted is expensive and, worse, it's often not what the patient wanted at all. Palliative support at home tends to reduce hospitalizations. So you get the outcome that health economists find suspicious because it's too good: less suffering and lower cost, arriving together. It only reads as a paradox if you've never watched a family navigate the end of a life. Vynca's bet is that the cheapest care and the most humane care are, more often than the system assumes, the same care.

Which is a convenient bet, because it aligns the incentives correctly. In a value-based arrangement, Vynca gets paid to keep people well and out of the hospital, not to bill for procedures. The company's own framing - helping people spend more quality days at home - happens to be exactly what a capitated payer wants too. When the humane thing and the profitable thing agree, you have a durable business. When they don't, you have a press release.

Total funding sits north of $50 million. The investor roster is worth reading closely: these are longevity funds, health-focused venture firms, and growth investors like Questa Capital who specialize in exactly this kind of value-based care company. They are not tourists. They are betting, with some conviction, that the model - patient-centered serious illness care, delivered flexibly, paid for by aligned payers - is not just good ethics but good business.

The trailing signals point the same direction. In 2025, Vynca named Dr. Jill Schwartz-Chevlin as Chief Medical Officer and added Sandra Clarke to its board, the sort of clinical and governance depth a company assembles when it intends to scale rather than exit. Twelve years in, Vynca is still building - which, in a sector where health systems earn trust in years rather than sprints, is roughly the correct pace.